Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Dodge & Cox Stock I

Vanguard Total Stock Mkt Idx Inv

iShares Core S&P 500 ETF

T. Rowe Price Mid-Cap Value

T. Rowe Price US Mid-Cap Value Equity

Vanguard Value Index Inv

The Health Care Select Sector SPDR® ETF

Vanguard Mid-Cap Value ETF

Invesco S&P 500® Equal Weight ETF

Franklin Mutual Shares Z

Vanguard Institutional Index I

Bridge Builder Large Cap Value

Vanguard Institutional 500 Index Trust

Vanguard Mid Cap Index Institutional

BlackRock Equity Dividend Instl

Oakmark Investor

SPDR® S&P 500® ETF Trust

Fidelity 500 Index

Pzena Large Cap Value

Vanguard Windsor Investor Shares

BlackRock Inc

Vanguard Group Inc

Amvescap Plc.

Camber Capital Management LLC

NORGES BANK

State Farm Mutual Automobile Ins Co

Nordea Investment Mgmt Bank Demark A/s

Macquarie Group Ltd

Morgan Stanley - Brokerage Accounts

LSV Asset Management

Northern Trust Corp

Franklin Resources Inc

Dodge & Cox

Pzena Investment Management, LLC

State Street Corp

T. Rowe Price Associates, Inc.

Bank of New York Mellon Corp

Geode Capital Management, LLC

Ameriprise Financial Inc

Harris Associates L.P.

Baxter International Inc

Mr. Jose E. Almeida

Chairman of the Board, President & CEO

Mr. Joel T. Grade

Executive VP, CFO & Interim Chief Accounting Officer

Ms. Heather  Knight

Executive VP & Group President of Medical Products and Therapies

Mr. Alok  Sonig B.E., Mba

Executive VP & Group President of Pharmaceuticals

Mr. Christopher A. Toth

Executive VP & Group President of Kidney Care

Ms. Tobi  Karchmer M.D., M.S.

Senior VP and Chief Medical & Scientific Officer

Mr. Charles Rusty Patel

Senior VP & Chief Information Officer

Ms. Clare  Trachtman

Vice President of Investor Relations

Mr. David S. Rosenbloom

Executive VP & General Counsel

Ms. Stacey  Eisen

Senior Vice President, Chief Communications Officer & Corporate Marketing?

BAX's next earnings is on February 6, 2025 (Before Market Open)

BAX's latest dividend is 0.29 USD on August 30, 2024

Baxter International Inc (BAX) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Baxter International Inc (BAX) Earnings Report Date and History | NYSE

BAX's next earnings is on February 6, 2025 (Before Market Open)

When is the earnings report for BAX?

BAX Earnings History

BAX's latest dividend is 0.29 USD on August 30, 2024

BAX Stock Discussion Forum and Message Board

News for NYSE: BAX